These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8517688)

  • 21. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
    van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum.
    Wallace RJ; Brown BA; Silcox VA; Tsukamura M; Nash DR; Steele LC; Steingrube VA; Smith J; Sumter G; Zhang YS
    J Infect Dis; 1991 Mar; 163(3):598-603. PubMed ID: 1995732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Port-site infections by nontuberculous mycobacterium: A retrospective clinico-microbiological study.
    Ghosh R; Das S; De A; Kela H; Saha ML; Maiti PK
    Int J Mycobacteriol; 2017; 6(1):34-37. PubMed ID: 28317802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the in vitro susceptibility of 220 Mycobacterium fortuitum isolates to ten antimicrobial agents.
    Hernández AM; Arias A; Felipe A; Alvarez R; Sierra A
    J Chemother; 1995 Dec; 7(6):503-8. PubMed ID: 8667033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.
    Van der Auwera P; Klastersky J
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1061-8. PubMed ID: 3116918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
    Chu HS; Chang SC; Shen EP; Hu FR
    PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium kansasii.
    Fabry W; Schmid EN; Ansorg R
    Chemotherapy; 1995; 41(4):247-52. PubMed ID: 7555204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
    Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
    Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
    Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
    J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
    Rastogi N; Goh KS; Bryskier A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activities of quinolones against mycobacteria.
    Garcia-Rodriguez JA; Gomez Garcia AC
    J Antimicrob Chemother; 1993 Dec; 32(6):797-808. PubMed ID: 8144420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
    Abshire R; Cockrum P; Crider J; Schlech B
    Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility of Mycobacterium marinum to dihydromycoplanecin A and ten other antimicrobial agents.
    Arai H; Nakajima H; Kaminaga Y
    J Dermatol; 1990 Jun; 17(6):370-4. PubMed ID: 2384640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
    Rodriguez Díaz JC; López M; Ruiz M; Royo G
    Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.
    Dalovisio JR; Pankey GA
    J Infect Dis; 1978 Mar; 137(3):318-21. PubMed ID: 632627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of photodynamic therapy on rapidly growing nontuberculous mycobacteria keratitis.
    Shih MH; Huang FC
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):223-9. PubMed ID: 20811055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].
    Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S
    Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.